Esperion Therapeutics Inc. has grabbed the spotlight with a drug that helps clear clogged arteries, but Pfizer Inc. could steal the show if it exercises its right to co-market the medicine and succeeds with its own experimental drug that bolsters “good” HDL cholesterol.
